Amaral André, Opal Steven M, Vincent Jean-Louis
Dept of Intensive Care, Erasme Hospital, Free University of Brussels, Belgium.
Intensive Care Med. 2004 Jun;30(6):1032-40. doi: 10.1007/s00134-004-2291-8. Epub 2004 May 18.
Coagulation abnormalities, ranging from a simple fall in platelet count to full-blown disseminated intravascular coagulation, are a common occurrence in critically ill patients and have been associated with increased mortality. In sepsis, activation of the extrinsic coagulation pathway by tissue factor induces increased coagulation, and simultaneous depression of the inhibitory mechanisms of coagulation, and suppression of the fibrinolytic system results in a procoagulant state that may lead to the formation of microvascular thrombi disturbing organ microcirculation and promoting the development of organ dysfunction. Many inflammatory mediators are involved in the activation of coagulation, but many coagulation proteins are themselves actively involved in the inflammatory process. In this article, we explore the complex relationship between inflammation and coagulation and how improved understanding of this interaction has led to the development of new therapeutic agents for patients with severe sepsis.
凝血异常,从血小板计数的简单下降到全面的弥散性血管内凝血,在重症患者中很常见,并且与死亡率增加有关。在脓毒症中,组织因子对外源性凝血途径的激活导致凝血增加,同时凝血抑制机制受到抑制,纤维蛋白溶解系统受到抑制,从而导致促凝状态,这可能会导致微血管血栓形成,扰乱器官微循环并促进器官功能障碍的发展。许多炎症介质参与凝血的激活,但许多凝血蛋白本身也积极参与炎症过程。在本文中,我们探讨了炎症与凝血之间的复杂关系,以及对这种相互作用的深入理解如何促成了针对严重脓毒症患者的新型治疗药物的开发。